Drug interaction study tests cancer Drug's effect on diabetes medication
NCT ID NCT05469113
First seen Jan 04, 2026 · Last updated Jun 20, 2026 · Updated 33 times
Summary
This completed Phase 1 study in 16 healthy adults looked at whether taking multiple doses of selpercatinib (a cancer drug) changes how the body processes repaglinide (a diabetes medication). Participants received both drugs in a fixed order, and researchers measured drug levels in the blood over 12 days. The goal was to gather safety and drug interaction information, not to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Celerion
Tempe, Arizona, 85283, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Selpercatinib (also known as LOXO-292) and repaglinide
What this could lead to
If successful, this study could help doctors understand how to safely combine selpercatinib with other drugs that are broken down similarly in the body.
What could go wrong
This is a small, early-stage study in healthy volunteers, not patients. It only looks at drug levels, not actual treatment effects, so results may not apply to real-world use.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.